<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>Shahid Bahonar University of Kerman and Iranian Biotechnology Society</PublisherName>
				<JournalTitle>Agricultural Biotechnology Journal</JournalTitle>
				<Issn>2228-6705</Issn>
				<Volume>18</Volume>
				<Issue>2</Issue>
				<PubDate PubStatus="epublish">
					<Year>2026</Year>
					<Month>05</Month>
					<Day>22</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Investigation the role of PCSk9 and IL-6 genes polymorphism in patients with CVD</ArticleTitle>
<VernacularTitle>Investigation the role of PCSk9 and IL-6 genes polymorphism in patients with CVD</VernacularTitle>
			<FirstPage>189</FirstPage>
			<LastPage>204</LastPage>
			<ELocationID EIdType="pii">5297</ELocationID>
			
<ELocationID EIdType="doi">10.22103/jab.2026.26573.1829</ELocationID>
			
			<Language>FA</Language>
<AuthorList>
<Author>
					<FirstName>Eman Redha</FirstName>
					<LastName>Omran</LastName>
<Affiliation>Medical Biotechnology Department, College of Biotechnology, Al-Qasim Green University, Babylon, 51013, Iraq.</Affiliation>
<Identifier Source="ORCID">0009-0009-5512-1348</Identifier>

</Author>
<Author>
					<FirstName>Abbas Abed</FirstName>
					<LastName>Sharhan</LastName>
<Affiliation>Medical Biotechnology Department, College of Biotechnology, Al-Qasim Green University, Babylon, 51013, Iraq.</Affiliation>
<Identifier Source="ORCID">0000-0001-7361-8555</Identifier>

</Author>
<Author>
					<FirstName>Nktel Faiz Nassir</FirstName>
					<LastName>Al-Saad</LastName>
<Affiliation>Medical Biotechnology Department, College of Biotechnology, Al-Qasim Green University, Babylon, 51013, Iraq.</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2025</Year>
					<Month>12</Month>
					<Day>20</Day>
				</PubDate>
			</History>
		    <Abstract>ObjectiveCardiovascular diseases are one of the most important causes of death worldwide. Research has shown that genetic and inflammatory factors play an important role in their occurrence. The aim of this study was to investigate the association of PCSK9 and IL-6 gene polymorphisms with cardiovascular diseases and to evaluate the status of lipid profile and inflammatory markers in affected patients.Materials and methods In this case-control study, 90 blood samples were collected from the Shahid Al-Mehrab Medical Center for Cardiac Diseases and Surgery at Marjan Teaching Hospital. The time period of this study was October 2023 to March 2024. Of these, 60 samples were from patients with cardiovascular diseases aged 30 to 70 years and 30 samples were from healthy individuals. Lipid profile including total cholesterol, triglycerides, LDL, VLDL and HDL were measured. Serum levels of PCSK9 and IL-6 and PCSK9 rs505151 and IL-6 −174G/C polymorphisms were also examined.ResultsThe results showed that patients with cardiovascular diseases had a significant increase in total cholesterol, triglycerides, LDL and VLDL and a significant decrease in HDL compared to the healthy group. Serum PCSK9 levels were significantly higher in patients. This could play a role in lipid metabolism disorders, vascular inflammation and the development of atherosclerosis. Examination of the PCSK9 rs505151 polymorphism showed that the protective GG genotype was less observed in patients and the AG and AA genotypes and the A allele were more observed in patients. In contrast, there was no significant difference in the genotypic distribution of the IL-6 −174G/C polymorphism between the two groups. However, serum IL-6 levels were significantly increased in patients.ConclusionsThe findings of this study suggest that PCSK9 gene polymorphisms may be associated with an increased risk of cardiovascular disease, while IL-6 acts more as an inflammatory marker than a direct genetic risk factor. These results may be useful in identifying individuals at risk and designing effective prevention and treatment strategies.</Abstract>
			<OtherAbstract Language="FA">ObjectiveCardiovascular diseases are one of the most important causes of death worldwide. Research has shown that genetic and inflammatory factors play an important role in their occurrence. The aim of this study was to investigate the association of PCSK9 and IL-6 gene polymorphisms with cardiovascular diseases and to evaluate the status of lipid profile and inflammatory markers in affected patients.Materials and methods In this case-control study, 90 blood samples were collected from the Shahid Al-Mehrab Medical Center for Cardiac Diseases and Surgery at Marjan Teaching Hospital. The time period of this study was October 2023 to March 2024. Of these, 60 samples were from patients with cardiovascular diseases aged 30 to 70 years and 30 samples were from healthy individuals. Lipid profile including total cholesterol, triglycerides, LDL, VLDL and HDL were measured. Serum levels of PCSK9 and IL-6 and PCSK9 rs505151 and IL-6 −174G/C polymorphisms were also examined.ResultsThe results showed that patients with cardiovascular diseases had a significant increase in total cholesterol, triglycerides, LDL and VLDL and a significant decrease in HDL compared to the healthy group. Serum PCSK9 levels were significantly higher in patients. This could play a role in lipid metabolism disorders, vascular inflammation and the development of atherosclerosis. Examination of the PCSK9 rs505151 polymorphism showed that the protective GG genotype was less observed in patients and the AG and AA genotypes and the A allele were more observed in patients. In contrast, there was no significant difference in the genotypic distribution of the IL-6 −174G/C polymorphism between the two groups. However, serum IL-6 levels were significantly increased in patients.ConclusionsThe findings of this study suggest that PCSK9 gene polymorphisms may be associated with an increased risk of cardiovascular disease, while IL-6 acts more as an inflammatory marker than a direct genetic risk factor. These results may be useful in identifying individuals at risk and designing effective prevention and treatment strategies.</OtherAbstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">cardiovascular disease</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">gene polymorphism</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">IL-6</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">lipoprotein</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">PCSK9</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://jab.uk.ac.ir/article_5297_bf5a1d9043100645b2067fa70d7a1ea6.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
